Journal
CANCER CELL
Volume 40, Issue 5, Pages 458-478Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2022.04.002
Keywords
-
Categories
Funding
- Royal Society [RSRP\R\210001]
- Francis Crick Institute from Cancer Research UK [FC001169]
- UK Medical Research Council [FC001169]
- Wellcome Trust [FC001169]
- Cancer Research UK [C11496/A17786, C416/A21999]
- CRUK Cancer Immunotherapy Catalyst Network)
- Cancer Research UK Lung Cancer Centre of Excellence [C11496/A30025]
- Rosetrees Trust
- Butterfield Trust
- Stoneygate Trust
- NovoNordisk Foundation [16584]
- Royal Society Professorship Enhancement Award [RP/EA/180007]
- National Institute for Health Research (NIHR) Biomedical Research Center at University College London Hospitals
- Cancer Research UK-University College London Center
- Experimental Cancer Medicine Center
- Breast Cancer Research Foundation [BCRF 20-157]
- Stand Up To CancerLUNGevity-American Lung Association Lung Cancer Interception Dream Team Translational Research Grant [SU2C-AACR-DT23-17]
- ERC Advanced Grant (PROTEUS) from the European Research Council under the European Union's Horizon 2020 research and innovation programme [835297]
- CRUK
- IASLC International Lung Cancer Foundation
- Lung Cancer Research Foundation
- UKI NETs
- NIHR
- NIHR UCLH Biomedical Research Centre
Ask authors/readers for more resources
The translational challenges in the field of precision oncology are partly due to the complexity and diversity of cancer. Advances in genomics have enabled large-scale sequencing efforts and discoveries, impacting our understanding of cancer initiation, prevention, treatment, and other concepts. Key areas for improving cancer outcomes are discussed, along with the practical challenges of adopting molecular profiling in clinical settings and the need for robust translational infrastructure.
The translational challenges in the field of precision oncology are in part related to the biological complexity and diversity of this disease. Technological advances in genomics have facilitated large sequencing efforts and discoveries that have further supported this notion. In this review, we reflect on the impact of these dis-coveries on our understanding of several concepts: cancer initiation, cancer prevention, early detection, adjuvant therapy and minimal residual disease monitoring, cancer drug resistance, and cancer evolution in metastasis. We discuss key areas of focus for improving cancer outcomes, from biological insights to clinical application, and suggest where the development of these technologies will lead us. Finally, we discuss practical challenges to the wider adoption of molecular profiling in the clinic and the need for robust translational infrastructure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available